Western Australia, Australia: Patients authorized to consume plant-derived oral cannabis products show sustained improvements in their symptoms, according to longitudinal data published in the journal PLOS Once. Researchers assessed the long-terms safety and efficacy of oral cannabis products in a cohort of nearly 4,000 Australian patients authorized to use them. Study participants were naïve to cannabis prior to their enrollment in the trial. The …
Genova, Italy: The daily consumption of a proprietary oromucosal spray containing equal ratios of plant-derived THC and CBD (nabiximols aka Sativex) is not associated with cardiovascular complications in stroke survivors, according to clinical data published in the journal Frontiers in Cardiovascular Medicine. A team of Italian researchers assessed the safety of nabiximols in a cohort of 34 spasticity patients that had previously suffered from strokes. …
London, United Kingdom: Patients with post-traumatic stress experience symptom improvements following the use of cannabis products, according to data published in the journal Expert Review of Neurotherapeutics. British investigators assessed the safety and efficacy of cannabis products in 162 PTSD patients with a physician’s authorization. Study subjects were participants in the UK Medical Cannabis Registry. Study participants consumed either cannabis extracts or THC-dominant flowers for …
Los Angeles, CA: Subjects who consume commercially available CBD products report improvements in their overall well-being as compared to those taking a placebo, according to data published in the journal Integrative Medicine Reports. A team of investigators affiliated with the University of California, Los Angeles and with the Scripps Institute assessed the health and safety of 13 commercially available CBD products in a cohort …
New South Wales, Australia: The majority of available data fails to support claims that cannabis may potentially impact either cognitive function or subjects’ performance of safety sensitive tasks 24 hours after consumption, according to a review of the scientific literature published in the journal Cannabis and Cannabinoid Research. A team of Australian researchers reviewed data from 20 studies involving 458 subjects. Selected studies assessed …
CARY, N.C., Dec. 12, 2022 (GLOBE NEWSWIRE) — Sleep is so vital to human health that the NIH says lack of it can lead to chronic illnesses. Most Americans don’t get enough sleep – despite knowing how important rest is to one’s health. One group of health practitioners can help – Chiropractors are doing their part to ensure their patients sleep better, and …
New York, NY: The adoption of statewide medical cannabis access laws is associated with lower rates of opioid use and with a reduction in the number of pain-related hospitalizations among newly diagnosed patients with cancer, according to data published in the journal JAMA Oncology. Investigators affiliated with Cornell University’s Weill Medical College assessed the relationship between medical cannabis legalization and opioid-related and pain-related outcomes …
Melbourne, Australia: Children with autism spectrum disorder (ASD) show significant improvements in their symptoms following the use of plant-derived CBD dominant extracts, according to phase 1 trial results reported by Australian media. Patients in the trial consumed extracts containing CBD and other non-THC phyto-cannabinoids twice daily for a period of at least two months. Researchers affiliated with the study said that patients experienced …
San Antonio, TX: Medical cannabis retail access is inversely associated with drug overdose mortality rates, according to the findings of a literature review published in the journal Drug and Alcohol Dependence. Investigators affiliated with the University of Texas and Arizona State University reviewed data from over 50 studies highlighting county-level predictors of overdose mortality. “[M]easures related to cannabis dispensaries, substance use treatment, social capital, and proportions of family …
Chicago, IL: The administration of a proprietary transdermal CBD gel (aka ZYN002) is safe and effective in patients with Fragile X syndrome (FXS), according to phase 3 clinical trial data published in the Journal of Neurodevelopmental Disorders. FXS is a genetic disorder resulting in developmental delays, learning disabilities, and behavioral problems, such as aggression and attention deficits. Over 200 pediatric patients (mean age 9.7 years) participated in …